#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Myelodysplastic syndrome with excess blasts Ewing's sarcoma metastatic Dedifferentiated liposarcoma Biliary neoplasm VEXAS syndrome Thrombocytopenia Paget's disease of the vulva Angiosarcoma recurrent Non-Hodgkin's lymphoma unspecified histology aggressive recurrent Malformation venous Crigler-Najjar syndrome Ocular myasthenia Barth syndrome Graft versus host disease Cold type haemolytic anaemia More trials…

    Learn about Rare Diseases

    Gaucher’s disease type I – Diagnostics Toxic epidermal necrolysis – Diagnostics Marginal zone lymphoma refractory – Treatment Haemophagocytic lymphohistiocytosis – Life with Disease Primary biliary cholangitis – Trials in Disease Rhabdoid tumour – Treatment CADASIL – Treatment Antithrombin III deficiency – Diagnostics Burkitt’s lymphoma – Treatment Angiosarcoma recurrent – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    TRIACYLGLYCEROL LIPASE Edoxaban Azathioprine Clofarabine Dexibuprofen BI-1607 Daptomycin Obinutuzumab Vortioxetine INCB123667 Ketamine Hydrochloride Hydralazine Hydrochloride 177LU-PSMA-I&T Glycerol Phenylbutyrate Pemetrexed Disodium Quizartinib Dihydrochloride Bendamustine Vudalimab Ly3484356 AUR200 More therapies…

    Learn about Your Condition

    Hypoalbuminaemia Transplant rejection Pulmonary congestion Adenomyosis Brain injury Solitary fibrous tumour Intestinal obstruction Hepatobiliary disease Brain abscess Peyronie's disease Chondrosarcoma metastatic Niemann-Pick disease Behcet's syndrome Cirrhosis alcoholic Rabies More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Comparing Two Treatment Lengths of Cetuximab, Avelumab, Cisplatin, and Docetaxel for Patients with Returning Spread Head and Neck Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Head and neck cancer metastatic
    Investigated Drugs:
    • Avelumab
    • Carboplatin
    • Cetuximab
    Germany

  • A Study of Gilteritinib to Eliminate Remaining Cancer Cells in Patients with Acute Myeloid Leukemia and FLT3-ITD Mutation

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Gilteritinib
    Greece

  • Testing Stem Cell Transplant Methods and Medications Including Ruxolitinib and Blinatumomab for Children and Young Adults with Acute Lymphoblastic Leukemia

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Allogenic stem cell transplantation
    Investigated Drugs:
    • Anti-T Lymphocyte Immunoglobulin For Human Use, Rabbit
    • Blinatumomab
    • Busulfan
    Austria Belgium Czechia Denmark Finland France +6

  • A Study of CRN09682 for Patients with Neuroendocrine Tumors and Other Solid Tumors that Express Somatostatin Receptor Type 2

    Recruiting

    2 1 1
    Investigated Diseases:
    • Neuroendocrine tumour
    • Neoplasm
    France Germany Italy Spain

  • A Study of Tarperprumig Safety and Effectiveness in Adults with Blood Vessel Inflammation Caused by ANCA Antibodies

    Recruiting

    2 1
    Investigated Diseases:
    • Anti-neutrophil cytoplasmic antibody positive vasculitis
    France Germany Italy Poland Spain

  • A Study of Idecabtagene Vicleucel CAR-T Cell Therapy for Patients with Autoimmune Diseases That Did Not Respond to B Cell Removal Treatment

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Idiopathic inflammatory myopathy
    • Systemic lupus erythematosus
    • Systemic scleroderma
    Investigated Drugs:
    • Idecabtagene Vicleucel
    Germany
Previous Page
1 … 96 97 98 99 100 … 1,646
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!